High Cost Drugs Identified
As Payers continue to struggle with the surge in both the volume and cost of specialty drugs, RGA has identified a list of 180+ costly specialty drugs with their associated estimated costs.
The full report and tool (available solely to RGA Reinsurance clients) serves as a resource to educate and inform healthcare professionals about high-cost drugs. For the scope of the tool and report, high-cost drugs were defined as costing greater than $50,000 annually or $7,000 monthly. The cost cited is the lesser of the cost to cure the disease (e.g. Hepatitis C) or 12 months of treatment. The exception to this definition is if a lower cost drug is routinely paired with a higher cost drug (e.g.: Hepatitis C drugs), then it is also listed in this report. Costs were based on Wholesale Acquisition Costs (WAC), which is a drug-price data point that represents a manufacturer-reported “list price,” at which, that manufacturer will sell a medication to a wholesaler. Like Average Wholesale Price (AWP), WAC is not based on actual sales information, and it is usually higher than the price at which a manufacturer will sell a drug to a wholesaler. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price.
Research was conducted using both scholarly and public health resources on the Internet and via public and proprietary databases. Sources used are identified in the “sources” worksheet within the tool.
When Data Was Available This Report Identifies